Loading
A phase 2/3 trial of Nabilone in Non-small-cell lung cancer, run by Instituto Nacional de Cancerologia de Mexico, with a status the registry has not verified recently.
Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients is a phase 2/3 interventional study registered as NCT02802540 by Instituto Nacional de Cancerologia de Mexico, with 78 participants planned, started 2014-12 and due to reach its primary completion in 2017-07. Interventions recorded: Nabilone, Placebo. Conditions recorded: Non-Small Cell Lung Cancer, Anorexia, Cachexia, Weight Lose.
Linked to the drug Nabilone because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/